Lipid metabolism in ferroptosis and ferroptosis-based cancer therapy

Yonghao Sun¹, Zuoxing Xue²†, Tao Huang¹*, Xiangyu Che¹* and Guangzhen Wu¹*

¹Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, China, ²Department of Urology, Dalian University Affiliated Xinhua Hospital, Dalian, China

Ferroptosis refers to iron-dependent, specialized, and regulated-necrosis mediated by lipid peroxidation, which is closely related to a variety of diseases, including cancer. Tumor cells undergo extensive changes in lipid metabolism, including lipid peroxidation and ferroptosis. Changes in lipid metabolism are critical for the regulation of ferroptosis and thus have important roles in cancer therapy. In this review, we introduce the characteristics of ferroptosis and briefly analyze the links between several metabolic mechanisms and ferroptosis. The effects of lipid peroxides, several signaling pathways, and the molecules and pathways involved in lipid metabolism on ferroptosis were extensively analyzed. Finally, our review highlights some ferroptosis-based treatments and presents some methods and examples of how these treatments can be combined with other treatments.

KEYWORDS
lipid metabolism, ferroptosis, tumor, tumor therapy, lipid peroxidation

1 Feature of ferroptosis

The discovery of ferroptosis stemmed from the identification of systematic xCT in 1980 (1). It was not until 2012 that Dixon al. formally proposed the concept of ferroptosis (2). And ferroptosis is morphologically, biochemically and genetically different from other regulated cell death (RCD).

1.1 Morphological characteristics

The morphology of ferroptosis cells is significantly different from other RCD. Macroscopically, ferroptosis cells show swelling of the cytoplasm as well as organelles,
deformation of the plasma membrane, and decreased chromatin condensation similar to necrosis (3, 4). Microscopically, ferroptosis cells show abnormalities in the mitochondrial structure, such as mitochondrial outer membrane rupture, an increase in mitochondrial membrane density, and reduced or even disappearance of the mitochondrial cristae.

1.2 Biochemical characteristics

Abnormal iron and lipid metabolism in ferroptosis is obvious, iron is a key factor in lipid oxidation and ferroptosis, and abnormalities in its input, secretion, distribution, and storage can affect ferroptosis (5, 6). Mitochondria is an important organelle involved in the production of ROS (7), and lipid peroxides are type of ROS that directly induce ferroptosis (8). Normal cellular biological processes require the participation of ROS, but excessive ROS will destroy cellular components and lead to cell death (9). Two signaling axes, Xc⁻/GSH/GPX4 and FSP1/DHODH/CoQ10 protect cells from ferroptosis. Specific regulatory factors and mechanisms are detailed below (Figure 1).

Current research shows that ferroptosis is inextricably linked to amino acid, glucose, iron, and lipid metabolism. Glutamate and glutamine involved in the amino acid pathway regulate ferroptosis (10). Cysteine input through system Xc⁻ belongs to the amino acid pathway, and the transsulfurization pathway allows cells to convert methionine to cysteine. The mitochondrial TCA cycle and electron transport chain can promote cysteine deprivation-induced ferroptosis, the process involving amino acid metabolism, lipid metabolism, and glucose metabolism (11).

2 Lipid peroxidation and ferroptosis

Excessive accumulation of lipid peroxides is an important link in the process of ferroptosis, and substrates and enzymes involved in lipid peroxidation can regulate ferroptosis.

2.1 Key substrates and enzymes of lipid peroxidation

Ferroptosis is accompanied by the accumulation of lipid peroxides. Lipidomics analysis showed that PEs containing AA or epinephrine AdA in the membrane phospholipid family are susceptible to lipid peroxidation (12). Acyl-CoA synthetase long-chain family member 4 (ACSL4) and lysophosphatidylcholine acyltransferase 3 (LPCAT3) can acylate AA/AdA to membrane phospholipids, affect the properties of PUFA, and play important regulatory roles in ferroptosis (13, 14).

ACSL4 is an indispensable enzyme for lipid metabolism that catalyzes the binding of free long-chain fatty acids to CoA and preferentially recognizes arachidonic acid, and acylates it (15), after which LPCAT3 catalyzes the acylated AA into PL (14). The inhibition of these two enzymes can block the accumulation of lipid peroxides during ferroptosis, thus inhibiting ferroptosis to a certain extent. In addition, FSP1 catalyzes the conversion of ubiquinone to ubiquinol and prevents lipid peroxidation in the cell membranes (16).

2.2 Oxygenases in lipid peroxidation

Lipid peroxidation can be divided into enzymatic and non-enzymatic reactions (17), which the latter mainly refer to the entry of iron into cells through transferrin, followed by the Fenton reaction with hydrogen peroxide where excess oxygen free radicals are generated (18). Lipid oxidases involved in enzymatic reactions are divided into three types, namely lipoxygenase (LOX), cytochrome P450 oxidoreductase (POR), and cyclooxygenase (COX). The production of ROS requires the participation of these enzymes, furthermore, these enzymes are involved in ferroptosis (19). PUFA substrates are oxidized in the U-shaped fatty acid-binding channels of LOXs (20), the LOX gene family consists of six members: ALOX3, ALOX5, ALOX12, ALOX12B, ALOX15, and ALOX15B (21). TP53 is a tumor suppressor gene that suppresses the expression of SLC7A11 to deplete GSH, thus inducing ferroptosis (22). Different members of TP53 can induce ferroptosis via different ALOX (21, 23). Cytochrome P450 oxidoreductase (POR) can use electrons derived from the donor NADPH and provide them to downstream effectors (such as CYP and cytochrome p50) to reduce them. This causes the peroxidation of membrane polyunsaturated phospholipids which can lead to ferroptosis (24). COX-2 is upregulated during ferroptosis, however, inhibition of COX-2 does not modulate ferroptosis.

3 Lipid metabolism regulates ferroptosis

Compared with normal cells, the lipid metabolism of tumor cells is abnormal, and lipid metabolism is widespread in the process of ferroptosis. Fatty acid synthesis, fatty acid transport, the mevalonate pathway for cholesterol synthesis, and several major signaling pathways involved in lipid metabolism regulate ferroptosis.

3.1 PUFA and MUFA

PUFA play a unique and important role in regulating cell death, AA and AdA are the most critical substrate in ferroptosis.
Hypermethylation of the promoter region results in low expression of ELOVL5 and FADS1 in intestinal-type gastric cancer (GC) cells, which are resistant to ferroptosis, and after supplementation with AA, the cells become ferroptosis-sensitive (25).

Treatment of cells with exogenous MUFA inhibits ferroptosis, and this protective effect is dependent on the involvement of ACSL3 (26). The mechanism is associated with the inhibition of ROS accumulation in the plasma membrane by MUFA, which competes with PUFA for binding to phospholipids. Increasing the ratio of saturated fatty acids (SFA) to monounsaturated fatty acids (MUFA) in cells, leads to lipotoxicity and apoptosis (27). The mechanism by which MUFA inhibits ferroptosis is distinct from its mechanism of inhibiting lipotoxicity by directing SFA into the triglyceride pool to form lipid droplets, which ultimately protects cells from lipotoxicity (28).

3.2 De novo synthetic pathway

Normal cells rely on glucose as their primary energy source, and excess glucose is used for de novo lipogenesis. SFA and MUFA can be produced through this pathway, while PUFA level is dependent on dietary intake (29), glucose in cancer cells is used for anabolism rather than for generating oxidative energy (30). Approximately 95% of the fatty acids in tumor cells are derived from endogenous synthesis (31, 32). De novo synthesized fatty acids are stored in neutral lipids (stored in the LD) and phospholipids (in the membrane), and lipid synthesis is exuberant in cancer cells. Lipid droplets act as potential scavengers of ROS and promote de novo lipid synthesis in cancer cells (33, 34), the presence of lipid droplets inhibits cell ferroptosis to a certain extent.

3.3 Fatty acid intake

In addition to de novo synthesis of fatty acids, fatty acid transporters such as fatty acid translocase (FAT/CD36), fatty acid transporter (FATP), and fatty acid-binding protein (FABP) can transport extracellular fatty acids into the cells (35). Similar to normal cells, cancer cells utilize exogenous lipids when de novo synthesis is inhibited (36).

The cluster of differentiation 36 (CD36) can be involved in fatty acid intake, and increased CD36 expression can lead to tumor metastasis. Blocking CD36 can inhibit tumor growth and metastasis in prostate cancer models (37). Fatty acid taken via CD36 is mostly stored rather than used for fatty acid oxidation, which may promote ferroptosis in CD36-overexpressing tumor cells (38). On the other hand, CD36 can suppress ferroptosis by exporting AA (39).

Besides CD36, FATP2 is also responsible for mediating fatty acid uptake. Selective inhibition of FATP2 can delay tumor progression, while loss of FATP2 leads to impaired uptake of AA, making cells resistant to ferroptosis (40). FATP2 expression...
was reduced in GC cells, but the cells enhanced their ability to synthesize fatty acids through de novo fatty acid synthesis so that AA deficiency had minimal effect, allowing cells to remain sensitive to ferroptosis (25).

3.4 Mevalonate pathway

Cholesterol can be oxidized and is an important component of the cell membrane structure and lipoprotein, studies have shown that cholesterol and ferroptosis have many links (41, 42). In addition to de novo synthesis of FAs and cholesterol by liver and adipocytes, cholesterol can also be synthesized via the mevalonate pathway, in which hydroxymethylglutaryl-CoA reductase (HMGCR) is the rate-limiting enzyme (43). Many enzymes associated with de novo synthesis and/or mevalonate pathway synthesis are thought to inhibit tumor growth (36, 44). The mevalonate pathway also affects selenoprotein biosynthesis (45), and GPX4 is a form of selenoprotein, thus, so the mevalonate pathway is related to ferroptosis. Statins have been used clinically for cholesterol-lowering therapy since their development (46), and they were later found that patients taking statins were resistant to some tumors, such as breast cancer (47). Statins can inhibit HMG-CoA reductase (HMGCR), resulting in the inactivation of GPX4 and induction of ferroptosis in mesenchymal cancer cells (48). FIN56 is a class III FIN that degrades GPX4 and activates squalene synthase (SQS), which can lead to the exhaustion of coenzyme Q10 (CoQ10), leading to ferroptosis (49), moreover, its mechanism of action involves the mevalonate pathway.

3.5 Signaling pathways regulate ferroptosis

In addition to GPX4 and FSP1, there are also several signaling pathways involved in lipid metabolism that can regulate ferroptosis: the Hippo pathway involved in cell proliferation and regulation of cell size, the AMPK signaling involved in energy metabolism, and the HIF pathway involved in hypoxic conditions (50, 51). The regulatory mechanisms of these three pathways and their involvement in lipid metabolism are summarized in Table 1.

4 Ferroptosis-related cancer treatment

4.1 Ferroptosis-based drug therapy

4.1.1 Iron metabolism-related drug therapy

There is widespread dysregulation of iron metabolism in well-known cancer types, such as breast cancer, pancreatic cancer, lymphoma, hepatocellular carcinoma, glioblastoma, prostate cancer, and colorectal cancer (77). Regulation of ferroptosis via iron metabolism is a reliable approach for the treatment of different cancer types. Artesunate enhances the lysosomal activity and increases the lysosomal iron concentration in cells (78). Furthermore, it regulates the mRNA expression levels of iron-related genes (79), the expression of NCOA4 to promote ferritin phagocytosis to increase the cellular iron concentration, and other processes which can induce ferroptosis (80). Artesunate regulates iron metabolism through the above-mentioned mechanisms and induces ferroptosis in pancreatic cancer cells (81). Artesunate also inhibits Burkitt lymphoma by inducing ferroptosis (82). Dihydroartemisinin increases the autophagic degradation of ferritin by accumulating in lysosomes, increasing the cellular

| Signaling pathway | Mechanism | Involved in lipid metabolism | Refs |
|------------------|-----------|-----------------------------|------|
| E-cadherin-NF2-Hippo-YAP | Downstream effector TAZ alters cell density | no | (52, 53) |
| | YAP affects ferroptosis by regulating target genes ACSL4 and TR1 | yes | (54) |
| Cadherin affects cell-to-cell contact and EMT by regulating the Hippo pathway | no | (55) |
| AMPK | Activation of AMPK inhibits ferroptosis by inhibiting lipid peroxidation | yes | (56) |
| | AMPK promotes ferroptosis by directly blocking system Xc activity | yes | (57) |
| HIF-2α-HILPDA | HIF-2α-HILPDA axis selectively enriches polyunsaturated lipids by activating the expression of hypoxia-inducible factors | yes | (58, 59) |
iron content, and inducing ferroptosis (78, 83), thereby triggering ferroptosis in glioma cells (84). Cisplatin, which is involved in ferritin phagocytosis and leads to an increase in cellular free iron levels, also induces ferroptosis (85). In a cisplatin-resistant head and neck cancer cell model, the treatment effect of artesunate was poor, and the inhibition of the NRF2-ARE pathway increased the sensitivity of artesunate and reversed the ferroptosis resistance of the model (86). Changes in iron metabolism were also involved in this process.

4.1.2 Lipid peroxidation-related drug therapy

The two signal axes mentioned earlier, system Xc-/GSH/GPX4 axis and FSP1/DHODH/CoQ10 axis, as well as transcription factor NERF2, p53 gene, and three types of lipid

---

**TABLE 2** This table summarizes examples of radiation therapy, chemotherapy, immunotherapy, and other combination of treatments, and briefly describes the mechanism.

| Therapy       | Treatment  | Combination drugs | Mechanism                                                                 | Refs |
|---------------|------------|-------------------|---------------------------------------------------------------------------|------|
| Radiotherapy  | RT         | FINs              | Up-regulates ACSL4, inhibits SLC7A11 or GPX4                              | (64) |
| Chemotherapy  | Bortezomib | Iron              | Increases intracellular iron content to induce ferroptosis               | (65) |
|               | doxorubicin and cisplatin | microRNA miR-133a | Targeted downregulation of ferritin light chain (FTL) protein          | (66) |
| Statins       | --         | FINs              | Reduces selenoproteins (such as GPX4) and CoQ10 biosynthesis             | (67) |
| Cyst(e)inase  | --         | FINs              | Depletes extracellular cystine                                           | (16) |
| Sorafenib     | siRNA      |                  | Inhibits the system Xc-                                                  | (68) |
| Immunotherapy | PD-L1 inhibitors | FINs       | Releases IFN-γ to reduce the uptake of cystine                           | (69) |
|               | photodynamic therapy | --          | Increases the level of lymphocyte infiltration in tumors and recruits immune cells to secrete IFN-γ | (70) |
| Nanotherapy   | Nanoparticle materials | Iron        | Increases intracellular iron content and activates the Fenton response  | (71) |
|               | Sorafenib and Cisplatin |                  | Increases the sensitivity of cancer cells to drugs                       | (72), (73) |
|               | PUFA       |                  | Regulates lipid peroxidation                                              | (74), (75) |
|               | exosomes   | erastin           | Avoids adverse reactions                                                  | (76) |

---

**FIGURE 2**
Mechanisms by which some treatments affect ferroptosis and tumors. Radiation therapy can generate ROS, induce lipid peroxidation, upregulate ASCL4, promote PUFA synthesis, provide a substrate for lipid peroxidation, deplete GSH and affect GPX4 to affect ferroptosis. IFN-γ in immunotherapy can affect system Xc-, which further affects ferroptosis through the GPX4 pathway. PD-L1 can directly inhibit tumors. Nanotherapy can deliver iron and chemotherapeutic drugs to cells to achieve better therapeutic effects. The impact of the immune microenvironment on ferroptosis and tumors cannot be ignored.
oxidase: COX, cytochrome POR, and LOX, can serve as targets for regulating lipid peroxidation. In terms of regulating the lipid peroxidation pathway, gemcitabine is the main treatment drug for Pancreatic ductal adenocarcinoma (PDAC), which leads to the accumulation of ROS and induces ferroptosis when it exerts its therapeutic effect (87). Inhibition of the HSPA5-GPX4 pathway can induce and provoke ferroptosis in PDAC cells and enhance the anticancer effect of gemcitabine (88). Sorafenib can directly inhibit the function of system Xc- and activate the NRF2-SLC7A11 signaling pathway. The use of the NRF2 inhibitor trigonelline in a sorafenib-treated mouse model was found to promote ferroptosis and enhance the tumor suppressor effect of sorafenib (68). In a glioblastoma multiforme (GBM) model, temozolomide (TMZ) induces SLC7A11 expression by activating NRF2 and ATF4, which partially inhibits ferroptosis (89).

4.2 Combining ferroptosis with other treatments

4.2.1 Radiation therapy

Radiation therapy can induce various types of DNA damage in cells (90) and produce highly reactive OH radicals and other ROS by stimulating oxidase activity (91, 92), making it capable of inducing ferroptosis. The ionizing radiation produced by radiotherapy induces ferroptosis in three ways (93): 1. Production of excess ROS to induce lipid peroxidation. 2. Up-regulation of ACSL4 expression which further promotes PUFA-PL biosynthesis. 3. GSH consumption inhibits the protective effects of GPX4 on ferroptosis. The combination of radiation therapy and ferroptosis inducers such as erastin and sulfasalazine (SAS) for class I FIN, RSL3 and ML162 for class II FIN, and FIN56 for class III FIN increases tumor sensitivity to radiation therapy. Studies have shown that these ferroptosis inducers combined with radiation therapy increase the sensitivity of non-small cell lung cancer cells to radiation therapy and achieve better therapeutic effects than conventional radiotherapy (64). Recent studies have shown that the combination of class I FIN and radiotherapy for SLC7A11 has a better effect, while class II and class III FIN have poor pharmacokinetic effects and are prone to cytotoxicity in actually combined therapy, and the overall therapeutic effect is not as good as that of class I FIN in combination with radiation therapy (92).

4.2.2 Chemotherapy

At present, based on iron and lipid metabolism, two important factors related to ferroptosis, some effective drugs and methods for reversing tumor resistance have been discovered. Inhibition of ferroptosis-related genes and pathways in tumor cells is thought to be one of the reasons for drug resistance (94, 95).

Regarding iron metabolism, initial studies have shown that TFR is associated with tumor drug resistance, and down-regulation of TFR can reverse tumor drug resistance (96). Ferritin levels in multiple myeloma cells are thought to be directly related to bortezomib resistance, iron supplementation in multiple myeloma cell lines increases cell death, and ferritin reduction allows tumor cells to overcome bortezomib resistance (65). After targeted down-regulation of the ferritin L subunit by microRNA miR-133a in cisplatin and doxorubicin-resistant breast cancer cells, the cells showed increased sensitivity to these drugs (66).

Cells with high expression of GSH and the light chain subunit XCT in system Xc- exhibit resistance to drugs and radiation via lipid metabolism-related pathways (97, 98). The drug resistance of tumor cells is believed to originate from its dependence on GPX4, and inhibition of GPX4 can induce ferroptosis and attenuate the drug resistance of tumor cells (99). FSP1 acts as an oxidoreductase in the plasma membrane to reduce CoQ and inhibit lipid peroxidation and ferroptosis, a pathway thought to be parallel to the GSH/GPX4 axis (16), this pathway also shows the potential of anti-tumor drug resistance (100); in a mouse model established using ferroptosis-resistant H460 lung cancer cell xenografts, the inhibition of FSP1 resulted in significant tumor suppression in both GPX4 KO and GPX4 KO/FSP1 KO groups (16).

4.2.3 Immunotherapy

The role of ferroptosis in regulating tumor immunity is bidirectional. It not only kills tumors, but also upregulates immune checkpoints and the production of immunosuppressive mediators can promote tumor growth. Interferon-gamma (IFN-γ) released from CD8+ T cells downregulates the expression of SLC3A2 and SLC7A11 in system Xc-, leading to ferroptosis in mouse model tumor cells (69). Another study reported that IFN-γ secreted by CD8+ lymphocytes upregulates PD-L1 in ovarian cancer cells, promoting tumor growth (101). Therefore, it is speculated to imagine that the combination of immune checkpoint inhibitors and ferroptosis therapy may have a notable effect. TAMs are M2 polarized macrophages that secrete vascular endothelial growth factor (VEGF) to promote tumor growth (102). IFN-γ inhibits TAM differentiation in the tumor microenvironment and converts TAMs to M1 macrophages (103, 104), M1 macrophages are more resistant to ferroptosis than M2 macrophages, and studies have shown that nitric oxide synthase (iNOS)/NO regulates macrophage ferroptosis resistance, and decreased levels of iNOS result in decreased ferroptosis resistance in M1 cells, whereas NO donors increase ferroptosis resistance in M2 cells (105). Photodynamic therapy can increase tumor lymphocyte infiltration and recruit immune cells to secrete IFN-γ and enhance ferroptosis (70), which involves complex regulation of the immune microenvironment. The combination of ferroptosis and immunotherapy has broad prospects in the future, but the complexity of the immune microenvironment of tumor cells, the positive and negative effects of ferroptosis in tumor regulation, and
the toxicity of ferroptosis-inducing agents on organisms require further in-depth experiments and inquiry.

4.2.4 Nanotherapy
Ferroptosis-based nanotherapeutics are currently under development, nanomaterials are generally divided into iron-based and non-iron-based nanomaterials. Iron-containing nanoparticulate materials can release iron to the tumor site and trigger the Fenton reaction to generate ROS, which induces ferroptosis (71). Chemotherapeutic drugs or ferroptosis inducers can be loaded into iron-based nanoparticles, such as sorafenib and cisplatin, to work more effectively (72, 73). Non-iron-based nanomaterials are iron-free in the first place, and they can function by carrying ferroptosis-inducing agents, carrying lipids, carrying non-coding RNAs, etc (106). PUFA can be supplemented by nanoparticle drugs, which can modulate lipid peroxidation and induce ferroptosis in tumor cells (74, 75). Furthermore, erastin has poor water solubility and is nephrotoxic, folic acid-labeled erastin-loaded exosomes were used in triple-negative breast cancer cells to avoid nephrotoxicity, and the treatment produced a good therapeutic effect (76). Tumor cell secretion of exosomal PD-L1 suppresses T cell activity, blocks immune checkpoints, and may lead to resistance to therapy (107). Nanounits constructed from exosome inhibitors and ferroptosis inducers can link the immunogenic advantage of exosome inhibition with ferroptosis, this is a new and effective immunotherapy strategy (106).

Conclusion and opinion
There is a wide range of metabolic abnormalities associated with ferroptosis. This abnormal regulation of metabolic pathways occurs in many diseases, especially cancer. Researchers have discovered some regulatory substances, pathways, genes, enzymes, and other components involved in ferroptosis. The presence of these target sites makes it possible to achieve disease treatment by regulating ferroptosis. In this review, we summarize and present the link between lipid metabolism and ferroptosis, with a focus on treatments that modulate ferroptosis by regulating lipid metabolism, and in combination with other treatments to achieve tumor therapy. Although the roles of many related pathways and factors have been demonstrated and validated in different cancer models, there are still some issues that have not yet been resolved.

Cancer treatment by regulating ferroptosis has been confirmed and applied in experimental processes and clinical environments. However, there are indeed differences in the effects of in vitro experiments and in vivo treatment. The side effects of some treatment methods also limit their practical application. For different types of cancer, targeted therapy should be selected according to their characteristics. Combining ferroptosis-based treatment with other treatment methods to promote strengths and avoid weaknesses appears to be a better treatment strategy in the future.

Author contributions
XC and GW contributed to conception and design of the manuscript. YS wrote the first draft of the manuscript. YS, ZX and TH modified the manuscript. All authors contributed to the manuscript and approved the submitted version.

Funding
The PhD Start-up Fund of Liaoning Province from GW (2021-BS-209, Liaoning Province, 30000 CNY). Dalian Youth Science and Technology Star from GW (2021RQ010, Dalian, 100000CNY); Liaoning Provincial Department of Education(LJKZ0860).

Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References
1. Bannai S, Kitamura E. Transport interaction of l-cystine and l-glutamate in human diploid fibroblasts in culture. J Biol Chem (1980) 255:2372–6. doi:10.1016/S0021-9258(19)85990-X
2. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell (2012) 149:1060–72. doi:10.1016/j.cell.2012.03.042
3. Vanden Berghe T, Linkermann A, Jouan-Lanhouet S, Walczak H, Vandenabeele P. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol (2014) 15:135–47. doi:10.1038/nrm3737
4. Newton K, Manning G. Necroptosis and inflammation. Annu Rev Biochem (2016) 85:743–63. doi:10.1146/annurev-biochem-060815-014830
fase.2021.765859
Proc Natl Acad Sci USA
BR. peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. (2019) 575:688
j.prostaglandins.2019.106363
metabolism.
Human haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death.
Biophys Acta
et al. Differentially localized acyl-CoA synthetase 4 isoenzymes mediate the 13:81
j.molcel.2018.10.042
et al. Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and mitochondria in ferroptosis.
Cell Chem Biol
17. doi:10.1038/nchembio.1416
19. Shintoku R, Takigawa Y, Yamada K, Kubota C, Yoshimoto Y, Takeuchi T, et al. Differentially localized acyl-CoA synthetase 4 isoenzymes mediate the metabolic channeling of fatty acids towards phosphatidylcholine. Biochim Biophys Acta (2014) 1841:227-39. doi: 10.1016/j.bbabio.2013.10.018
14. Dixon SJ, Winter GE, Musavi LS, Lee ED, Snijder B, Rebsamen M, et al. Lipoxygenase-mediated generation of lipid peroxides enhances ferroptosis. FEBS J (2017) 284:988-96. doi:10.1111/febs.14413
18. Tang Z, Huang Z, Huang Y, Chen T, Huang M, Liu H, et al. Ferroptosis: The silver lining of cancer treatment. Front Cell Dev Biol (2021) 9:768599. doi: 10.3389/fcell.2021.768599
19. Shintoku R, Takigawa Y, Yamada K, Kubota C, Yoshimoto Y, Takeuchi T, et al. Lipoxigenase-mediated generation of lipid peroxides enhances ferroptosis. ACS Chem Biol (2015) 10:164-9. doi: 10.1021/acschembio.0s00425
25. Kagan VE, Mao G, Qu F, Angelii JP, Doll S, Rebsamen M, et al. Dysregulation of the mevalonate pathway promotes carcinoma cell chemoresistance by promoting membrane lipid saturation. Cancer Res (2010) 70:1176-87. doi: 10.1158/0008-5472.CAN-09-3871
26. doi:10.1158/0008-5472.CAN-09-3871
27. Garbarino J, Sturley SL. Saturated with fat: new perspectives on lipotoxicity. Nature (2009) 464:1168-75. doi:10.1038/nature08913
28. Listenberger LL, Han X, Lewis SE, Caser S, Farese RV Jr, Opyr DS, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci USA (2003) 100:3077-82. doi:10.1073/pnas.0630588100
29. Lee JY, Kim WK, Baet KH, Lee SC, Lee EW. Lipid metabolism and ferroptosis. Biol (Basel) (2021) 10(4):184. doi: 10.3390/biol10040184
30. Carracedo A, Cantley LC, Pandolfi PP. Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer (2013) 13:227-32. doi:10.1038/nrc3483
31. Vazquez-Martin A, Colomer R, Brunet J, Luru R, Menendez JA. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Physiol (2008) 41:59-–85. doi:10.1111/j.1651-2240.2007.00498.x
32. Roghir F, Schulte A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer (2016) 16:732-–49. doi:10.1038/nrc2016.89
33. Kouzumis, Miyagi Y. Lipid droplets: A key cellular organelle associated with cancer cell survival under normoxia and hypoxia. Int J Mol Sci (2016) 17(9). doi:10.3390/ijms17091416
34. Rymann E, Brusselmann K, Scheye K, Timmermans L, Derau R, Münck S, et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res (2010) 70:1176-87. doi:10.1158/0008-5472.CAN-09-3871
35. Abumrad N, Coburn C, Ibrahim A. Membrane proteins implicated in long-chain fatty acid uptake by mammalian cells. CD3δ, FAP and FABP6. Biochim Biophys Acta (1999) 1441:14–13. doi:10.1016/S0006-8916(98)00137-7
36. Fernandez LP, de Cedron MG, de Molina AR. Alterations of lipid metabolism in cancer: Implications in prognosis and treatment. Front Oncol (2020) 10:77420. doi:10.3389/fonc.2020.777420
37. Pascual G, Augustinova A, Meijjta S, Martin M, Castellanos A, Attolini CS, et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature (2017) 541:1-–5. doi:10.1038/nature20791
38. Watt MJ, Clark AK, Selh LA, Hayes VR, Lister N, Rebello R, et al. Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. Sci Transl Med (2019) 11(478). doi:10.1126/scitranslmed.abb5758
39. Kuda O, Jenkins CM, Skinner JR, Moon SH, Xu S, Gross RW, et al. CD3δ protein is involved in store-operated calcium flux, phospholipase A2 activation, and production of prostaglandin E2. J Biol Chem (2011) 286:17785-–95. doi:10.1074/jbc.M111.232975
40. Vegila F, Tuyuin VA, Blasi M, De Leo A, Kossenkov AV, Dzendryldy R, et al. Fatty acid transport protein 2 reprograms neutrophils in cancer. Nature (2019) 569:73–8. doi:10.1038/s41586-019-1118-2
41. Zielinski ZA, Pratt DA. Cholesterol autoreoxidation revisited: Debunking the dogma associated with the most vtllified of lipids. J Am Chem Soc (2016) 138:6932-–5. doi:10.1021/jacs.6b03344
42. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol (2000) 1:31-–9. doi:10.1038/35060522
43. Clendening JW, Pandeya A, Boutros PC, El Ghamrasni S, Khosravi F, Trentin GA, et al. Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci USA (2010) 107:15651-–6. doi:10.1073/pnas.0910258107
44. Santos CR, Schulte A. Lipid metabolism in cancer. FERSJ (2012) 279:2610-–3. doi:10.1111/1440-1625.12465.680644.x
45. Bulthe AL, Chavatte L. Update on selenoprotein biosynthesis. Antioxid Redox Signal (2015) 23:775-–94. doi:10.1089/ars.2015.6391
46. Endo A. The discovery and development of HMGC-CoA reductase inhibitors. Lipid Res (1992) 33:1569-–82. doi:10.1194/jbc.269.24.26022
47. Cauley JA, McClueran A, Rodabough RJ, LaCroix A, Bauer DC, Margolis KL, et al. Statin use and breast cancer: prospective results from the women’s health initiative. J Natl Cancer Inst (2006) 98:760–7. doi:10.1093/jnci/dji188
48. Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature (2017) 547:453-–7. doi:10.1038/nature23807
49. Shimada K, Skouta R, Kaplan A, Yang WS, Hayano M, Dixon SJ, et al. Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nat Chem Biol (2016) 12:497-–503. doi:10.1038/nchembio.2079
50. Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Rev Mol Cell Biol (2021) 22:266-–82. doi:10.1007/s12935-020-00324-8
51. Zhao S, Li P, Wu W, Wang Q, Bli B, Li X, et al. Roles of ferroptosis in uremic malignancies. Cancer Cell (2021) 21:676. doi:10.1016/j.ccell.2021.07.025
52. Yang WH, Chi JT. Hippo pathway effectors YAP/TAZ as novel determinants of ferroptosis. Mol Cell Oncol (2020) 7:1699375. doi:10.3389/fonc.2020.71699375
53. Yang WH, Ding CC, Sun T, Hsu D, Hsiu C, Hsu D, et al. The hippo pathway effector TAZ regulates ferroptosis in renal cell carcinoma. Cell Rep (2019) 28:2501-–8.e2504. doi:10.1016/j.celrep.2019.07.107
cancer cells with acquired resistance to doxorubicin and cisplatin.

Tryndyak VP, et al. Iron metabolism disturbances in the MCF-7 human breast cancer cell lines.

lipoprotein docosahexaenoic acid nanoparticles on cancer stem cells isolated from (+) T cells regulate tumour ferroptosis during cancer immunotherapy.

reactive oxygen species.

chemotherapy by iron oxide nanocarrier-mediated generation of highly toxic reactive oxygen species. Cancer Res (2013) 98:971
doi: 10.1002/cncr.29232

Zhou Z, Song J, Tian R, Yang Z, Yu G, Lin L, et al. Activatable single oxygen generation from lipid hydroperoxide nanoparticles for cancer therapy. Angew Chem Int Ed Engl (2017) 56:6492-6.
doi: 10.1002/anie.201701181

Sun et al. 10.3389/fonc.2022.941618

Frontiers in Oncology frontiersin.org 09
response to oxidative stress. Redox Biol (2015) 5:33–42. doi: 10.1016/j.redox.2015.03.003

99. Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature (2017) 551:247–50. doi: 10.1038/nature24297

100. Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature (2019) 575:693–8. doi: 10.1038/s41586-019-1707-0

101. Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, et al. IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer (2015) 112:1501–9. doi: 10.1038/bjc.2015.101

102. Wang FQ, Chen G, Zhu JY, Zhang W, Ren JG, Liu H, et al. M2-polarised macrophages in infantile haemangiomas: correlation with promoted angiogenesis. J Clin Pathol (2013) 66:1058–64. doi: 10.1136/jclinpath-2012-201286

103. Jeong SK, Yang K, Park YS, Choi YJ, Oh SJ, Lee CW, et al. Interferon gamma induced by resveratrol analog, HS-1793, reverses the properties of tumor associated macrophages. Int Immunopharmacol (2014) 22:303–10. doi: 10.1016/j.intimp.2014.07.004

104. Ni L, Lu J. Interferon gamma in cancer immunotherapy. Cancer Med (2018) 7:4509–16. doi: 10.1002/cam4.1700

105. Wu Y, Ye C, Luo M, Cen C, Qiu J, Zhang S, et al. Ferroptosis in cancer treatment. Another way to Rome. Front Oncol (2020) 10:571127. doi: 10.3389/fonc.2020.571127

106. Luo L, Wang H, Tian W, Li X, Zhu Z, Huang R, et al. Targeting ferroptosis-based cancer therapy using nanomaterials: strategies and applications. Theranostics (2021) 11:9937–52. doi: 10.7150/thno.65480

107. Poggio M, Hu T, Pai CC, Chu B, Belair CD, Chang A, et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell (2019) 177:414–27.e413. doi: 10.1016/j.cell.2019.02.016
Glossary

AA  trioxarachidonic acid
ACC  acetyl-CoA carboxylase
ACSL4  long-chain family member 4
ACSL3  acyl-CoA synthetase longchain family member 3
AdA  adrenal acid
ALOX  Arachidonate lipoxigenase
AMPK  5’adenosine monophosphate-activated protein kinase
ATP  adenosine triphosphate
BECN1  beclin 1
CD36  cluster of differentiation 36
CN-A  Cotylenin A
CoQ10  Coenzyme Q10
COX  cyclooxygenase
cPLA2  cytoplasmic phospholipase A2
CYP  Cytochrome P450
DHODH  dihydroorotate dehydrogenase
DPP4  dipeptidyl peptide 4
ECM  extracellular matrix
ELOVL5  elongase of very-long fatty acid 5
EMP1  epithelial membrane protein 1
EMT  epithelial-mesenchymal transition
FABP  fatty acid binding protein
FADS1  fatty acid desaturase 1
FAT  fatty acid translocase
FATP2  fatty acid transporter 2
Fer-1  ferrostatin-1
FIN  ferroptosis inducers
FP  farnesyl pyrophosphate
FSP1  ferroptosis suppressor protein1
GBM  glioblastoma multiforme
GC  gastric cancer
GPX4  glutathione peroxidase 4
GSH  g-L-glutamyl-L-cysteinylglycine
GSGG  glutathione disulfide
HIF  hypoxia-inducible factor
HILPDA  hypoxia-inducible lipid droplet-associated protein
HSPA5  heat shock protein family A member 5
IPP  isopentenyl pyrophosphate
KO  knock out
LD  lipid droplets
LOX  lipoxygenases
LPA  Lysophosphatidic Acid
LPAT3  lysophosphatidylcholine acyltransferase 3
ML162  molecular libraries 162
MUFA  monounsaturated fatty acids
NADPH  nicotinamide adenine dinucleotide phosphate
NCOA4  nuclear receptor coactivator 4
NOS  nitric oxide synthase NADPH oxidase 4
PE  phosphatidylethanolamine
PDAC  pancreatic ductal adenocarcinoma
PD-L1  Programmed cell death ligand 1
PEITC  phenethyl isothiocyanate
PLINs  perilipins
PMN-MDSC  polymorphonuclear myeloid-derived suppressor cell
POR  cytochrome
PRRs  pattern recognition receptors P450 oxidoreductase
RCD  regulated cell death
ROS  reactive oxygen species
RPUFA  polyunsaturated fatty acid
RSL3  Ras selective lethal 3
RSL5  Ras selective lethal 5
SAS  sultasalazine
SFA  saturated fatty acids
SLC3A2  Solute carrier family 3 member 2
SLC7A11  Solute carrier family 7 member 11
SQS  squalene synthase
STAT3  signal transducer and activator of transcription 3
TAM  Tyro3
Axl  and Mer
TAZ  transcriptional co-activator with PDZ-binding motif
TCA  tricarboxylic acid cycle
TCRs  T cell receptors
TFR1  ferrotransferrin receptor 1
TMZ  temozolomide
TNFR  tumor necrosis factor receptor
TP53  tumor protein 53
TRF  transferrin
YAP  yes-associated protein 1
VEGF  vascular endothelial growth factor.

(Continued)